Targeting macrophages by an aza-anthrapyrazole to ameliorate experimental autoimmune encephalomyelitis.

Abstract:

BACKGROUND:Multiple sclerosis (MS) is an immune-mediated neurodegenerative disease in the central nerve system, in which both innate and adaptive immune cells are involved. BBR3378, an aza-anthrapyrazole prevents experimental autoimmune encephalomyelitis (EAE), an inflammatory condition similar to MS, by antagonizing T cell autoimmune responses. Here, we report BBR3378's regulatory effect on macrophages. METHODS:EAE was induced in ten-week-old female C57BL/6 mice by immunization with myelin oligodendrocyte glycoprotein peptides followed by BBR3378 or sham treatment administered intraperitoneally, and clinical signs were assessed using a 0-5 scoring system. These mice were subjected to serum ELISA for cytokine IFNγ and TNFα levels, RT qPCR analysis of macrophage markers in isolated monocytes, and flow cytometry analysis for macrophage infiltration in the brain. Macrophages derived from primary monocytes and macrophage cell line RAW 264.7 were used to investigate BBR3378's effect on LPS-stimulated pro-inflammatory cytokine induction. RAW 264.7 cells expressing NF-κB-driven luciferase reporter were treated with LPS with or without BBR3378, and luciferase assays performed to assess the inhibition on NF-κB activation. LPS-induced activation of mitogen-activated protein kinases (MAPKs) with or without the presence of BBR3378 was also investigated by Western blot analysis. RESULTS:BBR3378 down-regulated cytokine-induced macrophage differentiation and activation in EAE mice, contributing to protection against macrophage infiltration in the brain and clinical symptoms from EAE. Treating macrophages with BBR3378 counteracted LPS-induced cytokine production via blocking activation of key signal molecules mediating inflammatory responses, such as NF-κB and MAPKs. CONCLUSIONS:These data suggest that in addition to T cells, BBR3378 can also target macrophages to attenuate the inflammation associated with EAE.

authors

Lin B,Launder D,Bailey DY,Assifuah FK,Miller OA,Conti HR,Du J,Koffman BM

doi

10.1016/j.msard.2020.102190

subject

Has Abstract

pub_date

2020-08-01 00:00:00

pages

102190

eissn

2211-0348

issn

2211-0356

pii

S2211-0348(20)30266-2

journal_volume

43

pub_type

杂志文章
  • Whole transcriptome analysis of multiple Sclerosis patients reveals active inflammatory profile in relapsing patients and downregulation of neurological repair pathways in secondary progressive cases.

    abstract:BACKGROUND:Multiple sclerosis (MS) is an inflammatory autoimmune neurologic disease that causes progressive destruction of myelin sheath and axons. Affecting more than 2 million people worldwide, MS may presents distinct clinical courses. However, information regarding key gene expression and genic pathways related to ...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102243

    authors: Nali LH,Olival GS,Sousa FTG,de Oliveira ACS,Montenegro H,da Silva IT,Dias-Neto E,Naya H,Spangenberg L,Penalva-de-Oliveira AC,Romano CM

    更新日期:2020-09-01 00:00:00

  • Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions.

    abstract:BACKGROUND:Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system (CNS) that preferentially targets the spinal cord and optic nerves. Increasing disability is accrued with each inflammatory attack. Disability has been shown to be an independent predictor of poor quality of...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.msard.2018.12.011

    authors: Mealy MA,Mossburg SE,Kim SH,Messina S,Borisow N,Lopez-Gonzalez R,Ospina JP,Scheel M,Yeshokumar AK,Awad A,Leite MI,Arango JJ,Paul F,Palace J,Kim HJ,Levy M

    更新日期:2019-02-01 00:00:00

  • Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis.

    abstract:BACKGROUND:Patient-reported outcomes (PROs) provide information on treatment effects from the patient's perspective that complement outcomes on clinical measures. In DECIDE, daclizumab demonstrated superior efficacy in reducing relapses, 24-week confirmed disability progression, and brain lesions (assessed by magnetic ...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.msard.2016.11.005

    authors: Liu Y,Vollmer T,Havrdova E,Riester K,Lee A,Phillips G,Wang P,Sabatella G

    更新日期:2017-01-01 00:00:00

  • Epidemiology and comorbidities of adult multiple sclerosis and neuromyelitis optica in Taiwan, 2001-2015.

    abstract:BACKGROUND:The epidemiology of multiple sclerosis (MS) and neuromyelitis optica (NMO) remains to be clarified or updated in many parts of Asia. This study aims to investigate the epidemiology and comorbidities of MS and NMO during 2001-2015 in Taiwan. METHODS:We conducted a retrospective nationwide population-based st...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102425

    authors: Fang CW,Wang HP,Chen HM,Lin JW,Lin WS

    更新日期:2020-10-01 00:00:00

  • Photophobia in multiple sclerosis.

    abstract:BACKGROUND:Photophobia has never been investigated in MS. METHODS:In this pilot study we used photosensitivity questionnaire assessment (PAQ) to evaluate tolerability to light in 73 MS patients and 62 healthy controls. RESULTS:We identified a lower PAQ score and a higher number of photophobic subjects in MS than in c...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.09.005

    authors: Cortese A,Conte A,Ferrazzano G,Sgarlata E,Millefiorini E,Frontoni M,Berardelli A

    更新日期:2018-11-01 00:00:00

  • Coexistent MOG, NMDAR, CASPR2 antibody positivity: Triumph over the triumvirate.

    abstract::Myelin oligodendrocyte glycoprotein (MOG) antibody (MOG -Ab) positive cases can have a focal encephalitis like presentation. Many reports of anti N-methyl-D-aspartate receptor (NMDAR) encephalitis have documented simultaneous coexistence of MOG-Ab which is explained by the coexpression of NMDA receptors and MOG on oli...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 信件

    doi:10.1016/j.msard.2020.102468

    authors: Cherian A,Divya KP,Shetty SC,Kannoth S,Thomas B

    更新日期:2020-11-01 00:00:00

  • Do neutralising antibodies against exogenous interferon-beta inhibit endogenous signalling pathways?

    abstract:INTRODUCTION:Interferon-beta (IFNβ) is currently the most used disease-modifying treatment for relapsing-remitting multiple sclerosis (RRMS), but it can lead to the production of neutralising antibodies (NABs) against IFNβ. CLINICAL CASE:A lady with a past history of genital herpes was diagnosed with RRMS, started IFN...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2014.11.007

    authors: Fine D,Dattani A,Moreira I,Giovannoni G,Marta M

    更新日期:2015-01-01 00:00:00

  • COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?

    abstract:BACKGROUND:Coronavirus disease 19 (COVID-19) is a novel disease entity that is spreading throughout the world. It has been speculated that patients with comorbidities and elderly patients could be at high risk for respiratory insufficiency and death. Immunosuppression could expose infected patients to even higher risks...

    journal_title:Multiple sclerosis and related disorders

    pub_type:

    doi:10.1016/j.msard.2020.102120

    authors: Novi G,Mikulska M,Briano F,Toscanini F,Tazza F,Uccelli A,Inglese M

    更新日期:2020-07-01 00:00:00

  • Development of a brief clinician-reported outcome measure of multiple sclerosis signs and symptoms: The Clinician Rating of Multiple Sclerosis (CRoMS).

    abstract:OBJECTIVE:No available assessment tool offers a brief and psychometrically sound way for clinicians to quantify assessment of MS in a typical office visit. The objective of this study was to develop a brief clinician-reported outcome measure of MS signs and symptoms to standardize and quantify assessments that occur du...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.06.024

    authors: Matza LS,Stewart KD,Phillips G,Delio P,Naismith RT

    更新日期:2019-10-01 00:00:00

  • Evaluation of types of psychological disorders in patients with neuromyelitis optica spectrum disorder (NMOSD).

    abstract:BACKGROUND:Neuromyelitis Optica Spectrum Disorder (NMOSD), commonly characterized by affecting optic nerves and spinal cord can be regarded as one of uncommon diseases of the central nervous system. Although the evidence presented in the literature supports cognitive impairments, psychological aspects of the disease an...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102128

    authors: Ebadi Z,Saeedi R,Hashemi SN,Gheini MR,Sahraian MA,Naser Moghadasi A

    更新日期:2020-07-01 00:00:00

  • Multiple intracranial lesions with lung adenocarcinoma: A rare case of MOG-IgG-associated encephalomyelitis.

    abstract:BACKGROUND:Myelin oligodendrocyte glycoprotein (MOG) is an important marker on the surface of oligodendrocytes and is associated with many demyelinating diseases. Recently, MOG-IgG-associated encephalomyelitis (MOG-EM) has been proposed as a disease entity with a preliminary diagnosis standard. Some patients with lung ...

    journal_title:Multiple sclerosis and related disorders

    pub_type:

    doi:10.1016/j.msard.2020.102064

    authors: Li K,Zhan Y,Shen X

    更新日期:2020-07-01 00:00:00

  • Prevalence of multiple sclerosis in Health District III, Murcia, Spain.

    abstract:BACKGROUND:The prevalence of multiple sclerosis (MS) varies throughout the world, and available epidemiological data suggest a progressively increasing prevalence of MS in Spain. The objective of this study was to calculate MS prevalence in Health District III of the autonomous community of Murcia in Spain. METHODS:Th...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2016.06.003

    authors: Candeliere-Merlicco A,Valero-Delgado F,Martínez-Vidal S,Lastres-Arias Mdel C,Aparicio-Castro E,Toledo-Romero F,Villaverde-González R

    更新日期:2016-09-01 00:00:00

  • CNS demyelination during tofacitinib therapy: First report.

    abstract::Iatrogenic demyelination is a distinct clinical subtype of central nervous system inflammatory disorders. The Janus kinase inhibitor, tofacitinib, is an oral disease-modifying antirheumatic drug that has shown contradictory effects on multiple sclerosis in animal models. In this report, we describe a novel case of rev...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 信件

    doi:10.1016/j.msard.2020.102568

    authors: Massoud F,Ismail II,Al-Hashel JY,Abboud H

    更新日期:2020-11-01 00:00:00

  • Erythroblastaemia in natalizumab-treated patients with multiple sclerosis.

    abstract:BACKGROUND:Natalizumab is a monoclonal antibody that significantly reduces the occurrence of relapses in relapse-remitting multiple sclerosis (RRMS) patients. Early papers on the clinical use of natalizumab in RRMS patients reported erythroblastemia as occasional and transient. OBJECTIVES:to determine the prevalence a...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2016.05.020

    authors: La Gioia S,Seghezzi M,Barcella V,Dominoni P,Mecca T,Frigeni B,Conti MZ,Vedovello M,Vidali M,Rottoli M,Buoro S

    更新日期:2016-07-01 00:00:00

  • Myelorradiculitis due to Varicella Zoster (Elsberg syndrome) as the first symptom of HIV in a patient with Crohn's disease in use of Infliximab.

    abstract::Elsberg syndrome (ES) refers to the combination of myelitis and lumbosacral radiculitis associated with infection caused by the virus of the Herpesviridae family. We present a case of a 52-year-old man with a 9 months diagnosis of Crohn's disease, in use of infliximab with good disease control, complaining of 2 months...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 信件

    doi:10.1016/j.msard.2020.102643

    authors: Santos DH,Carneiro de Oliveira RM,Junior WRF,Olivetti BC

    更新日期:2020-11-25 00:00:00

  • Prevalence of fatigue and its association with clinical features in progressive and non-progressive forms of Multiple Sclerosis.

    abstract:BACKGROUND:Fatigue is a complex and disabling symptom of Multiple Sclerosis (MS); however, there is conflicting evidence of the relationship between fatigue and clinical features of MS. Furthermore, few studies have considered these relationships specifically in a progressive MS population. AIMS:(1) estimate the preva...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.01.011

    authors: Rooney S,Wood L,Moffat F,Paul L

    更新日期:2019-02-01 00:00:00

  • Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial.

    abstract:BACKGROUND:The role that dietary interventions can play in multiple sclerosis (MS) management is of huge interest amongst patients and researchers but data evaluating this is limited. Possible effects of a very-low-fat, plant-based dietary intervention on MS related progression and disease activity as measured by brain...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.msard.2016.07.001

    authors: Yadav V,Marracci G,Kim E,Spain R,Cameron M,Overs S,Riddehough A,Li DK,McDougall J,Lovera J,Murchison C,Bourdette D

    更新日期:2016-09-01 00:00:00

  • Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies.

    abstract:BACKGROUND:Whilst there is a broad selection of drugs licensed as disease modifying treatments (DMTs) for people with relapsing multiple sclerosis (pwRMS), access to DMTs remains restricted, particularly for people with progressive MS (pwPMS). Cladribine has shown efficacy at all stages of MS. Following withdrawal from...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.11.001

    authors: Mao Z,Álvarez-González C,Allen-Philbey K,De Trane S,Yildiz O,Campion T,Adams A,Turner BP,Marta M,Gnanapavan S,Espasandin M,Mathews J,Giovannoni G,Baker D,Schmierer K

    更新日期:2019-01-01 00:00:00

  • Peak width of skeletonized mean diffusivity (PSMD) as marker of widespread white matter tissue damage in multiple sclerosis.

    abstract:BACKGROUND:Peak width of skeletonized mean diffusivity (PSMD) is a novel and fully automated, MRI biomarker, which has shown clinical relevance in cerebral small vessel diseases (SVD). We aimed here to assess PSMD levels across the brain of patients with multiple sclerosis (MS), in comparison to normal controls (NC) an...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.11.011

    authors: Vinciguerra C,Giorgio A,Zhang J,Di Donato I,Stromillo ML,Tappa Brocci R,Federico A,Dotti MT,De Stefano N

    更新日期:2019-01-01 00:00:00

  • Assessing the susceptibility to acute respiratory illness COVID-19-related in a cohort of multiple sclerosis patients.

    abstract:INTRODUCTION:Italy has been the first European country severely affected by the COVID-19 pandemic. OBJECTIVE:To analyze the incidence of the clinical presentations suggestive for COVID-19 infection among patients with Multiple Sclerosis in the province of Lecco, in the North Italy, the closest province capital to Berg...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102453

    authors: Mantero V,Abate L,Balgera R,Basilico P,Salmaggi A,Cordano C

    更新日期:2020-11-01 00:00:00

  • Effect of fingolimod (FTY720) on choroidal thickness in patients with multiple sclerosis.

    abstract:OBJECTIVE:Using spectral domain optical coherence tomography (SD-OCT), to compare the choroidal thickness in a healthy population (group 1), with newly diagnosed multiple sclerosis (MS) patients (group 2), with MS patients who underwent β-interferon monotherapy (group 3) and MS patients who underwent fingolimod therapy...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2017.03.005

    authors: Kal A,Oğuz Ulusoy M,Horasanlı B,Cezairlioğlu Ş,Kal Ö

    更新日期:2017-05-01 00:00:00

  • Levels of peripheral Th17 cells and serum Th17-related cytokines in patients with multiple sclerosis: A meta-analysis.

    abstract:BACKGROUND:Multiple reports have described the proportion of Th17 cells in peripheral blood and serum levels of Th17-related cytokines in patients with multiple sclerosis (MS). To clarify the status of Th17 cells and Th17-related cytokines in MS patients, we did a meta-analysis of the results published previously to as...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.msard.2017.09.003

    authors: Li YF,Zhang SX,Ma XW,Xue YL,Gao C,Li XY

    更新日期:2017-11-01 00:00:00

  • Application of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of Latin American patients.

    abstract:BACKGROUND:The 2015 International Panel for neuromyelitis optica (NMO) spectrum disorders (NMOSD) diagnosis (IPND) criteria was recently proposed. However, because there are no studies evaluating application of the IPND criteria in Latin American populations, we aimed to assess whether these new criteria improve the di...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.01.001

    authors: Carnero Contentti E,Soto de Castillo I,Daccach Marques V,López PA,Antunes Barreira A,Armas E,de Aquino Cruz C,Rubstein A,Lavigne Moreira C,Molina OM,Soto A,Tkachuk V

    更新日期:2018-02-01 00:00:00

  • Optic neuropathy: A 15-year retrospective observational study.

    abstract:BACKGROUND:Optic neuropathies (ON) have several aetiologies and sometimes the diagnosis established ab initio is redefined after further investigations and/or new neurological events. We aim with this study to report clinical, paraclinical findings, treatment choices and disease course in patients admitted with a suspi...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102337

    authors: Alves JM,Seabra M,Braz L,Guimarães J

    更新日期:2020-09-01 00:00:00

  • Upper limb rehabilitation interventions using virtual reality for people with multiple sclerosis: A systematic review.

    abstract:BACKGROUND:Research on Virtual Reality (VR) based motor rehabilitation for people with multiple sclerosis (MS) is rapidly growing in popularity, although few studies have focused on the upper limb (UL). The aims of this review were to investigate the effect of VR interventions on UL function in people with MS and deter...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,评审

    doi:10.1016/j.msard.2020.102610

    authors: Webster A,Poyade M,Rooney S,Paul L

    更新日期:2020-10-31 00:00:00

  • Construct validity and test-retest reliability of the Swedish version of the Acceptance of Chronic Health Conditions Scale.

    abstract::The Acceptance of Chronic Health Conditions Scale was developed to measure acceptance in chronic health conditions like multiple sclerosis (MS) and has been translated into Swedish (The Swedish Acceptance of Chronic Health Conditions Scale). The purpose of the present study was to evaluate construct validity and test-...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.07.033

    authors: Wallin A,Forslin M,Johansson S,Kierkegaard M

    更新日期:2019-10-01 00:00:00

  • Incidence of multiple sclerosis misdiagnosis in referrals to two academic centers.

    abstract:BACKGROUND:Multiple Sclerosis (MS) specialists routinely evaluate misdiagnosed patients, or patients incorrectly assigned a diagnosis of MS. Misdiagnosis has significant implications for patient morbidity and healthcare costs, yet its contemporary incidence is unknown. We examined the incidence of MS misdiagnosis in ne...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.01.048

    authors: Kaisey M,Solomon AJ,Luu M,Giesser BS,Sicotte NL

    更新日期:2019-05-01 00:00:00

  • Placebo controlled trials in neuromyelitis optica are needed and ethical.

    abstract::Currently, there are no approved treatments for NMO. All therapeutic studies in NMO have been either small, retrospective case series or uncontrolled prospective studies. Such studies are susceptible to inherent biases. As a consequence, conclusions regarding efficacy and safety from these studies may be erroneous. Th...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,评审

    doi:10.1016/j.msard.2015.07.017

    authors: Cree BA

    更新日期:2015-11-01 00:00:00

  • Cognitive and neuropsychiatric disorders among multiple sclerosis patients from Latin America: Results of the RELACCEM study.

    abstract:BACKGROUND:Cognitive impairment and psychiatric symptoms impact many aspects of the lives of people with multiple sclerosis [MS]. This literature is based largely on North American and Western European samples, and little is known about these aspects of MS disability in Latin America. OBJECTIVE:RELACCEM is a longitudi...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2013.10.007

    authors: Caceres F,Vanotti S,Benedict RH,RELACCEM Work Group.

    更新日期:2014-05-01 00:00:00

  • Real-world incidence of fingolimod-associated macular oedema.

    abstract:BACKGROUND:Fingolimod (Gilenya, Novartis, Basel Switzerland) 0.5 mg orally once-daily is widely used for relapsing-remitting multiple sclerosis. Patients are usually screened four months after starting fingolimod for fingolimod-associated macular oedema (FAME). Large registration trials with stringent eligibility crite...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102125

    authors: Goh LY,Kirthi V,Silber E,Harvey JP,Jackson TL

    更新日期:2020-07-01 00:00:00